Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

2024160 citationsJournal Articlegreen Open Access

Authors

Claire Roddie · University College London Hospitals NHS Foundation Trust

Karamjeet Sandhu · University College London Hospitals NHS Foundation Trust

Eleni Tholouli · University College London Hospitals NHS Foundation Trust

Aaron C. Logan · University College London Hospitals NHS Foundation Trust

Paul Shaughnessy · University College London Hospitals NHS Foundation Trust

Pere Barba · University College London Hospitals NHS Foundation Trust

Abstract

Obe-cel resulted in a high incidence of durable response among adults with relapsed or refractory B-cell ALL, with a low incidence of grade 3 or higher immune-related toxic effects. (Funded by Autolus Therapeutics; FELIX ClinicalTrials.gov number, NCT04404660.).

Topics & Keywords

CAR-T cell therapy research Acute Lymphoblastic Leukemia research Immune Cell Function and Interaction

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: New England Journal of Medicine

Volume 391, Issue 23, pp. 2219-2230

DOI: 10.1056/nejmoa2406526

Field-Weighted Citation Impact: 45.11